pyrazines has been researched along with Thrombopenia in 53 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (3.77) | 18.2507 |
| 2000's | 21 (39.62) | 29.6817 |
| 2010's | 28 (52.83) | 24.3611 |
| 2020's | 2 (3.77) | 2.80 |
| Authors | Studies |
|---|---|
| Egawa, K; Fujii, H; Fukushi, S; Furuta, Y; Harada, S; Komeno, T; Kurosu, T; Lim, CK; Maeki, T; Morikawa, S; Nakajima, N; Saijo, M; Shimojima, M; Takayama-Ito, M; Tani, H; Taniguchi, S; Uda, A; Yamada, S; Yoshikawa, T | 1 |
| Cash, T; Fox, E; Liu, X; Minard, CG; Reid, JM; Scheck, AC; Weigel, BJ; Wetmore, C | 1 |
| Bunworasate, U; Caguioa, PB; Choi, CW; Chung, JS; Comia, NS; Do, YR; Jootar, S; Jung, CW; Kim, DW; Kim, DY; Kim, H; Kim, HJ; Kim, JA; Kim, SH; Kong, JH; Kwak, JY; Lee, SE; Lee, WS; Mun, YC; Oh, SJ; Park, J; Park, JS; Reksodiputro, AH; Shin, HJ; Zang, DY | 1 |
| Arima, N; Baba, M; Okamoto, M; Saijo, M; Sakakibara, N; Toyama, M | 1 |
| Bahceci, E; Iida, H; Kaneko, M; Kobayashi, Y; Kusano, M; Miyamoto, T; Miyawaki, S; Morita, S; Naoe, T; Sakura, T; Takeshita, S; Usuki, K; Yamada, S | 1 |
| Saijo, M | 1 |
| Brioli, A; Cavo, M; Mancuso, K; Pantani, L; Perrone, G; Pezzi, A; Rocchi, S; Tacchetti, P; Tosi, P; Zamagni, E; Zannetti, BA | 1 |
| Comenzo, R; Cossor, F; Fallo, S; Kaul, E; Klein, A; Miller, K; Shah, G; Smith, H; Sprague, K | 1 |
| Cain, R; Waight, CC | 1 |
| Benevolo, G; Boccadoro, M; Bringhen, S; Cavo, M; Di Raimondo, F; Falcone, AP; Franceschini, L; Gaidano, G; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Magarotto, V; Marasca, R; Mina, R; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, ID; Zambello, R | 1 |
| Cavalli, M; Chiarenza, A; Conticello, C; Cunsolo, R; Di Raimondo, C; Di Raimondo, F; Palumbo, GA; Romano, A; Vetro, C | 1 |
| Fujishima, Y; Ishida, Y; Ito, S; Kowata, S; Murai, K; Shimoyama, T; Yashima-Abo, A | 1 |
| Ashcroft, AJ; Bird, JM; Brown, JM; Cairns, DA; Cavenagh, J; Cavet, J; Chalmers, A; Cook, G; Drayson, MT; Fletcher, M; Hunter, H; Morris, TC; O'Connor, S; Parrish, C; Snowden, JA; Williams, C; Yong, K | 1 |
| Curtis, BR; Davies, SM; Filipovich, AH; Grimley, MS; Jodele, S; Jordan, MB; Khandelwal, P; Marsh, R | 1 |
| Amin, HM; Angelo, LS; Falchook, GS; Hess, K; Hong, D; Howard, AN; Huang, M; Jackson, EF; Janku, F; Kurzrock, R; Lawhorn, KN; Naing, A; Ng, CS; Parkhurst, KL; Tannir, NM; Vishwamitra, D; Wheler, JJ | 1 |
| Becerra, C; Bence Lin, A; Braiteh, F; Calvo, E; Galsky, MD; Hurt, K; Hynes, SM; Jameson, G; Lin, J; McKane, S; McWilliams, R; Richards, D; Von Hoff, D; Wickremsinhe, ER | 1 |
| Chow, L; Eckhardt, SG; Gore, L; Lieu, C; Morrow, M; O'Bryant, CL; Pierson, AS; Tran, ZV; Wright, JJ | 1 |
| Alloway, RR; Arend, LJ; Brailey, P; Cardi, M; Everly, JJ; Everly, MJ; Govil, A; Mogilishetty, G; Rike, AH; Roy-Chaudhury, P; Susskind, B; Tevar, A; Wadih, G; Woodle, ES | 1 |
| Basu, S; Cavenagh, J; Cook, M; Craddock, C; Foot, N; Hallam, S; Harding, S; Joel, S; Oakervee, H; Odeh, L; Popat, R; Singer, C; Williams, C | 1 |
| Bahlis, NJ; Barr, PM; Cooper, BW; Dowlati, A; Fu, P; Gerson, SL; Horvath, N; Koc, ON; Lazarus, HM; Snell, MR | 1 |
| Biesma, B; Bosquée, L; Chan, KC; De Marinis, F; Gans, S; Germonpré, P; Gervais, R; Lee, JS; Makhson, A; Manikhas, G; Morgan, B; Park, K; Planchard, D; Ramlau, R; Reck, M; Scagliotti, GV; Szczesna, A; Vansteenkiste, J; von Pawel, J; Zhu, Y | 1 |
| Barosi, G; Campanelli, R; Facchetti, F; Fisogni, S; Gattoni, E; Goldberg, J; Guglielmelli, P; Hoffman, R; Marchioli, R; Vannucchi, AM | 1 |
| Fujieda, A; Ishibashi, M; Iwamoto, T; Katayama, N; Masuya, M; Okuda, M | 1 |
| Cheng, B; Cheung, YK; Lee, SM | 1 |
| Alimena, G; Breccia, M; Cilloni, D; D'Auria, F; Gottardi, E; Latagliata, R; Mandelli, F; Musto, P; Saglio, G; Sanpaolo, G | 1 |
| Akiba, T; Aotsuka, N; Matsuura, Y; Oguro, R; Satoh, M; Takada, K; Tani, Y; Wakita, H; Yamanaka, C | 1 |
| Khan, ML; Stewart, AK | 1 |
| Dean, J; Dickinson, M; Harrison, SJ; Januszewicz, H; Johnstone, R; Link, E; Neeson, P; Nichols, J; Prince, HM; Quach, H; Ritchie, DS; Ruell, S; Seymour, JF | 1 |
| Abonour, R; Anderson, KC; Bengoudifa, BR; Bourquelot, PM; de Magalhaes-Silverman, M; Goldschmidt, H; Hazell, K; Lonial, S; Matous, J; Siegel, D; Vij, R; Wolf, JL | 1 |
| Andrea, M; Bachmann, A; Hammerschmidt, D; Kreibich, U; Lindner, T; Niederwieser, D; Petros, S; Pönisch, W; Schwarz, M; Schwarzer, A; Wagner, I; Winkelmann, C; Zehrfeld, T | 1 |
| Alloway, RR; Girnita, AL; Hanseman, DJ; Sadaka, B; Schmidt, N; Shields, AR; Walsh, RC; Woodle, ES | 1 |
| Cazzola, M; Cocito, F; Corso, A; Mangiacavalli, S; Pascutto, C; Pochintesta, L; Pompa, A | 1 |
| Allietta, N; Angermund, R; Bladé, J; Blau, IW; Broer, E; Corradini, P; Dimopoulos, MA; Drach, J; Giraldo, P; Mitchell, V; Petrucci, MT; Teixeira, A | 1 |
| Chen, Q; Du, XL | 1 |
| Fine, H; Hess, K; Jaeckle, K; Kunschner, LJ; Kyritsis, AP; Yung, WK | 1 |
| Colson, K; Doss, DS; Swift, R; Tariman, J; Thomas, TE | 1 |
| Aguado, B; Alegre, A; Bladé, J; Esparís-Ogando, A; Gutiérrez, N; Mateo, G; Pandiella, A; San Miguel, JF; Schenkein, D | 1 |
| Adjei, AA; Alberti, D; Alberts, SR; Binger, K; Bruzek, L; Dy, GK; Erlichman, C; Hanson, LJ; Kaufmann, SH; Mandrekar, S; Marnocha, R; Pitot, HC; Thomas, JP; Tutsch, K; Wilding, G | 1 |
| Anderson, J; Anderson, KC; Barlogie, B; Berenson, JR; Esseltine, DL; Francis, D; Giusti, S; Giver, CR; Heffner, LT; Jagannath, S; Jaye, DL; Lonial, S; Orlowski, RZ; Richardson, PG; Schenkein, DP; Singhal, S; Torre, C; Waller, EK; Xiao, H | 1 |
| Bang, SM; Kim, BK; Kim, JH; Kim, NK; Lee, JH; Lee, JS; Lee, KW; Lee, ST; Na, II; Park, S; Shin, H; Song, EK; Yoon, SS; Yun, T | 1 |
| Balleari, E; Boccadoro, M; Bodenizza, C; Carella, AM; Cascavilla, N; Catalano, L; Cavallo, F; Dell'Olio, M; Falcone, A; Greco, MM; Guglielmelli, T; La Sala, A; Mantuano, S; Melillo, L; Merla, E; Musto, P; Nobile, M; Palumbo, A; Sanpaolo, G; Scalzulli, PR; Spriano, M; Zambello, R | 1 |
| Anagnostopoulos, A; Bitsaktsis, A; Castritis, E; Dimopoulos, MA; Kyrtsonis, MC; Pangalis, GA | 1 |
| Bladé, J; Boccadoro, M; Cavenagh, J; Glasmacher, A; Jagannath, S; Lonial, S; Ludwig, H; Orlowski, RZ; San Miguel, J; Sonneveld, P | 1 |
| Atanackovic, D; Ayuk, F; Kröger, N; Renges, H; Schieder, H; Zabelina, T; Zander, A | 1 |
| Richardson, P | 1 |
| Anderson, KC; Ben-Yehuda, D; Cavenagh, JD; Facon, T; Harousseau, JL; Irwin, D; Lonial, S; Richardson, PG; San Miguel, JF; Schuster, MW; Sonneveld, P; Stadtmauer, EA | 1 |
| Calderoni, A; Cornu, P; Freimann, H; Olie, R | 1 |
| Bold, R; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Lau, DH; Lenz, HJ; Ruel, C; Schenkein, DP; Shibata, S | 1 |
| Blaise, D; de Lavallade, H; El-Cheikh, J; Faucher, C; Fürst, S; Hardan, I; Michallet, M; Mohty, M; Nagler, A; Nicolini, FE; Revesz, D; Shimoni, A; Sobh, M | 1 |
| Berenson, JR; Hilger, J; Lee, SP; Mapes, R; Morrison, B; Nassir, Y; Swift, R; Vescio, RA; Wilson, J; Yang, HH; Yellin, O | 1 |
| Berezin, F; Janisch, L; Mick, R; Ratain, MJ; Schilsky, RL; Vogelzang, NJ | 1 |
| Bowling, MK; Donehower, RC; Grochow, LB; Long, GS; Noe, DA; Rowinsky, EK; Sartorius, SE | 1 |
| Drengler, RL; Eckhardt, SG; Felton, SA; Garner, AM; Hammond, LA; Hidalgo, M; Mallikaarjun, S; Patnaik, A; Rowinsky, EK; Siu, LL; Tammara, BK; Von Hoff, DD | 1 |
4 review(s) available for pyrazines and Thrombopenia
| Article | Year |
|---|---|
Pathophysiology of severe fever with thrombocytopenia syndrome and development of specific antiviral therapy.
Topics: Aged, 80 and over; Amides; Animals; Antiviral Agents; Bunyaviridae Infections; China; Female; Humans; Japan; Male; Mice; Mice, Knockout; Middle Aged; Mortality; Phlebovirus; Pyrazines; Republic of Korea; Syndrome; Thrombocytopenia | 2018 |
Recent advancements of bortezomib in acute lymphocytic leukemia treatment.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Gastrointestinal Diseases; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Endopeptidase Complex; Pyrazines; Signal Transduction; Thrombocytopenia; Valproic Acid | 2013 |
Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications.
Topics: Anemia; Antineoplastic Agents; Asthenia; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Approval; Drug Monitoring; Gastrointestinal Diseases; Humans; Hypotension; Multiple Myeloma; Neutropenia; Nurse's Role; Oncology Nursing; Patient Care Planning; Patient Education as Topic; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Quality of Life; Thrombocytopenia; Water-Electrolyte Imbalance | 2004 |
A practical update on the use of bortezomib in the management of multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Prognosis; Pyrazines; Survival Analysis; Thrombocytopenia | 2006 |
31 trial(s) available for pyrazines and Thrombopenia
| Article | Year |
|---|---|
A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515).
Topics: Adolescent; Central Nervous System Neoplasms; Checkpoint Kinase 1; Checkpoint Kinase 2; Child; Child, Preschool; Female; Humans; Leukopenia; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms; Neutropenia; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Thrombocytopenia; Young Adult | 2021 |
Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.
Topics: Adult; Benzamides; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neutropenia; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Thrombocytopenia; Treatment Outcome | 2017 |
Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study.
Topics: Aged; Aged, 80 and over; Aniline Compounds; Axl Receptor Tyrosine Kinase; Creatine Kinase; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Japan; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazines; Receptor Protein-Tyrosine Kinases; Thrombocytopenia; Treatment Outcome | 2018 |
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Maintenance Chemotherapy; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Peripheral Nervous System Diseases; Prednisone; Pyrazines; Thalidomide; Thrombocytopenia; Treatment Outcome | 2014 |
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label,
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Disease Progression; Doxorubicin; Female; Humans; Induction Chemotherapy; Intention to Treat Analysis; Male; Melphalan; Middle Aged; Multiple Myeloma; Neutropenia; Peripheral Nervous System Diseases; Proportional Hazards Models; Pyrazines; Recurrence; Retreatment; Salvage Therapy; Stem Cell Transplantation; Thrombocytopenia; Time Factors; Transplantation, Autologous | 2014 |
Bortezomib for refractory autoimmunity in pediatrics.
Topics: Adolescent; Adult; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Autoimmunity; Boronic Acids; Bortezomib; Child; Child, Preschool; Drug Administration Schedule; Female; Humans; Infant; Male; Neutropenia; Plasma Cells; Plasmapheresis; Proteasome Inhibitors; Pyrazines; Retrospective Studies; Rituximab; Thrombocytopenia | 2014 |
Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Breast Neoplasms; Carcinoma, Renal Cell; Fatigue; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Pyrazines; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Deoxycytidine; Fatigue; Female; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Phenylurea Compounds; Pyrazines; Thrombocytopenia; Young Adult | 2016 |
A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Pyrazines; Thrombocytopenia | 2009 |
Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Statistics, Nonparametric; Thrombocytopenia | 2009 |
Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Nervous System Diseases; Neutropenia; Opportunistic Infections; Pyrazines; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine | 2009 |
A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Therapy, Combination; Dyspnea; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pemetrexed; Pyrazines; Survival Analysis; Thrombocytopenia | 2010 |
Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition.
Topics: Adult; Aged; Angiogenesis Inhibitors; Bone Marrow; Boronic Acids; Bortezomib; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Primary Myelofibrosis; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Risk; Salvage Therapy; Thrombocytopenia; Treatment Failure; Young Adult | 2010 |
Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Diarrhea; Drug Administration Schedule; Erythroid Cells; Female; Fever; Gene Expression; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Thrombocytopenia; Treatment Outcome; WT1 Proteins | 2011 |
Carfilzomib: a novel second-generation proteasome inhibitor.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Hematologic Neoplasms; Humans; Multiple Myeloma; Neutropenia; Oligopeptides; Proteasome Inhibitors; Protein Binding; Pyrazines; Thrombocytopenia | 2011 |
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Depsipeptides; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Secondary Prevention; Survival Analysis; Thrombocytopenia | 2011 |
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Male; Metabolic Clearance Rate; Middle Aged; Multiple Myeloma; Nausea; Neutropenia; Panobinostat; Pyrazines; Recurrence; Remission Induction; Thalidomide; Thrombocytopenia; Treatment Outcome | 2012 |
Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Nitrosourea Compounds; Organophosphorus Compounds; Peripheral Nervous System Diseases; Pyrazines; Secondary Prevention; Severity of Illness Index; Survival Analysis; Thrombocytopenia | 2013 |
A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Drug Resistance, Neoplasm; Europe; Female; Gastrointestinal Diseases; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Prospective Studies; Protease Inhibitors; Pyrazines; Recurrence; Salvage Therapy; Thalidomide; Thrombocytopenia; Treatment Outcome | 2013 |
CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carbamates; Disease-Free Survival; Female; Glioma; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Pyrazines; Pyridines; Survival Rate; Thrombocytopenia; Treatment Outcome | 2002 |
A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; bcl-2-Associated X Protein; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle Proteins; Cell Line, Tumor; Cyclin E; Cyclin-Dependent Kinase Inhibitor p27; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; I-kappa B Proteins; Male; Middle Aged; Nausea; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Thrombocytopenia; Treatment Outcome; Tumor Suppressor Proteins; Vomiting | 2005 |
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Male; Mice; Mice, Inbred BALB C; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Risk Factors; Thrombocytopenia; Treatment Outcome | 2005 |
A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Korea; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pilot Projects; Pyrazines; Survival Analysis; Thrombocytopenia; Time Factors | 2005 |
Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Humans; Leukopenia; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Thrombocytopenia; Transplantation, Homologous | 2006 |
Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; CD3 Complex; Chronic Disease; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Herpes Zoster; Humans; Leukopenia; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Remission Induction; Stem Cell Transplantation; Thrombocytopenia; Transplantation, Homologous | 2006 |
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Chi-Square Distribution; Dexamethasone; Disease Progression; Disease-Free Survival; Fatigue; Glucocorticoids; Humans; Multiple Myeloma; Nausea; Neutropenia; Pyrazines; Risk; Thrombocytopenia | 2007 |
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; California; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Neutropenia; Proteasome Inhibitors; Pyrazines; Thrombocytopenia; Treatment Outcome | 2008 |
Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Pyrazines; Thrombocytopenia | 2008 |
Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Leukopenia; Male; Middle Aged; Pyrazines; Thrombocytopenia | 1994 |
Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent.
Topics: Adult; Aged; Antineoplastic Agents; Carbamates; Central Nervous System Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Pyrazines; Pyridines; Thrombocytopenia | 1997 |
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Differentiation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Pyrazines; Quinolines; Thrombocytopenia; Vomiting | 2000 |
18 other study(ies) available for pyrazines and Thrombopenia
| Article | Year |
|---|---|
Susceptibility of Type I Interferon Receptor Knock-Out Mice to Heartland Bandavirus (HRTV) Infection and Efficacy of Favipiravir and Ribavirin in the Treatment of the Mice Infected with HRTV.
Topics: Amides; Animals; Disease Models, Animal; Humans; Mice; Mice, Knockout; Phlebovirus; Pyrazines; Receptor, Interferon alpha-beta; Ribavirin; Solvents; Thrombocytopenia | 2022 |
Establishment of an antiviral assay system and identification of severe fever with thrombocytopenia syndrome virus inhibitors.
Topics: Amides; Amodiaquine; Animals; Antiviral Agents; Bunyaviridae; Bunyaviridae Infections; Cell Line; Chlorocebus aethiops; Fever; Humans; Microbial Sensitivity Tests; Pyrazines; Ribavirin; Thrombocytopenia; Virus Replication | 2017 |
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Evaluation; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Immunologic Factors; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Thrombocytopenia; Treatment Outcome | 2014 |
Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients.
Topics: Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Diarrhea; Drug Therapy, Combination; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Thrombocytopenia | 2013 |
Authorising bortezomib treatment prior to reviewing haematology results: a step toward home administration.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Administration Schedule; Drug Monitoring; Home Care Services; Humans; Middle Aged; Multiple Myeloma; Platelet Count; Predictive Value of Tests; Prospective Studies; Proteasome Inhibitors; Pyrazines; Risk Assessment; Risk Factors; Scotland; Severity of Illness Index; Thrombocytopenia; Time Factors; Treatment Outcome | 2014 |
Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Polyethylene Glycols; Pyrazines; Recurrence; Salvage Therapy; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2014 |
Bortezomib induces thrombocytopenia by the inhibition of proplatelet formation of megakaryocytes.
Topics: Amides; Animals; Antineoplastic Agents; Blood Platelets; Bone Marrow; Boronic Acids; Bortezomib; Colony-Forming Units Assay; Disease Models, Animal; Male; Megakaryocyte Progenitor Cells; Megakaryocytes; Mice; Multiple Myeloma; Platelet Count; Pyrazines; Pyridines; rho-Associated Kinases; Thrombocytopenia; Thrombopoiesis; Thrombopoietin | 2014 |
Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.
Topics: Acute Disease; Biopsy; Boronic Acids; Bortezomib; Creatinine; Graft Rejection; Humans; Immunosuppressive Agents; Isoantibodies; Kidney Transplantation; Paresthesia; Protease Inhibitors; Pyrazines; Thrombocytopenia; United States; United States Food and Drug Administration | 2008 |
Drug interaction between itraconazole and bortezomib: exacerbation of peripheral neuropathy and thrombocytopenia induced by bortezomib.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Interactions; Female; Humans; Itraconazole; Japan; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Secondary Prevention; Thrombocytopenia; Treatment Outcome | 2010 |
Continual reassessment method with multiple toxicity constraints.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Calibration; Clinical Trials, Phase I as Topic; Computer Simulation; Cyclophosphamide; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Epidemiologic Research Design; Humans; Lymphoma, Non-Hodgkin; Maximum Tolerated Dose; Models, Statistical; Neoplasms; Neurotoxicity Syndromes; Prednisolone; Probability; Pyrazines; Statistical Distributions; Thrombocytopenia; Vincristine | 2011 |
Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Female; Humans; Japan; Leukopenia; Male; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Retrospective Studies; Survival; Thalidomide; Thrombocytopenia; Time Factors | 2011 |
Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Multiple Myeloma; Nausea; Nitrogen Mustard Compounds; Prednisone; Pyrazines; Renal Insufficiency; Retrospective Studies; Thrombocytopenia; Treatment Outcome; Vomiting | 2012 |
Prospective evaluation of the toxicity profile of proteasome inhibitor-based therapy in renal transplant candidates and recipients.
Topics: Adult; Boronic Acids; Bortezomib; Female; Graft Rejection; Humans; Kidney Transplantation; Male; Middle Aged; Peripheral Nervous System Diseases; Prospective Studies; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Thrombocytopenia | 2012 |
Bortezomib is an efficient agent in plasma cell leukemias.
Topics: Anemia; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 3; Caspases; Cell Proliferation; Cell Survival; Female; Humans; Leukemia, Plasma Cell; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multiple Myeloma; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Pyrazines; Thrombocytopenia; Time Factors | 2005 |
Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Disease Progression; Drug Evaluation; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Salvage Therapy; Thrombocytopenia; Treatment Outcome; Waldenstrom Macroglobulinemia | 2005 |
Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Humans; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Recurrence; Thrombocytopenia; Treatment Outcome | 2006 |
Daily practice use of Bortezomib in relapsed/refractory multiple myeloma. Safety/efficacy results of a compassionate use program in Switzerland.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Diarrhea; Drug Administration Schedule; Fatigue; Female; Humans; Male; Medical Oncology; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Recurrence; Switzerland; Thrombocytopenia; Treatment Outcome | 2007 |
High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Fatigue; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Protease Inhibitors; Pyrazines; Retrospective Studies; Salvage Therapy; Survival Analysis; Thrombocytopenia; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2008 |